IndustryCompany release

Emmaus Q3 revenue falls to $1.9M after Endari licence; going-concern doubt flagged

🇺🇸 Emmaus Life Sciences, Inc. (EMMA) · Thu 19 Nov 2026

Emmaus Life Sciences reports a wider third-quarter net loss of $4.7M and $1.0M in cash, as its May licence deal with NeoImmuneTech moved Endari sales away from the company.

Emmaus Life Sciences reported results for the quarter ended 30 September 2026 on 18 November. Net revenue fell to $1.9M, down from $3.4M in the same quarter a year earlier.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Emmaus Life Sciences, Inc. ↗

Article written by VigiEye from the official source (Emmaus Life Sciences, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →